Xeris Biopharma (NASDAQ:XERS) Trading 4.7% Higher – Time to Buy?

Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) shot up 4.7% during trading on Friday . The company traded as high as $4.40 and last traded at $4.32. 971,657 shares were traded during mid-day trading, a decline of 47% from the average session volume of 1,820,396 shares. The stock had previously closed at $4.13.

Wall Street Analyst Weigh In

A number of brokerages have commented on XERS. Jefferies Financial Group restated a “buy” rating and issued a $6.00 target price (up from $4.00) on shares of Xeris Biopharma in a research note on Wednesday, January 29th. HC Wainwright restated a “buy” rating and issued a $8.00 target price (up from $6.60) on shares of Xeris Biopharma in a research note on Friday. Finally, Piper Sandler reiterated a “neutral” rating and set a $4.00 price objective (up from $3.00) on shares of Xeris Biopharma in a research note on Friday.

Xeris Biopharma Stock Up 2.7 %

The stock’s 50 day moving average price is $3.57 and its 200-day moving average price is $3.26. The stock has a market capitalization of $632.10 million, a P/E ratio of -9.42 and a beta of 2.32.

Hedge Funds Weigh In On Xeris Biopharma

A number of hedge funds and other institutional investors have recently modified their holdings of the business. China Universal Asset Management Co. Ltd. boosted its stake in shares of Xeris Biopharma by 10.3% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 31,611 shares of the company’s stock valued at $107,000 after purchasing an additional 2,954 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Xeris Biopharma by 4.5% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 80,388 shares of the company’s stock valued at $273,000 after acquiring an additional 3,447 shares in the last quarter. GPS Wealth Strategies Group LLC boosted its stake in Xeris Biopharma by 6.2% in the fourth quarter. GPS Wealth Strategies Group LLC now owns 66,925 shares of the company’s stock valued at $227,000 after acquiring an additional 3,900 shares in the last quarter. Janney Montgomery Scott LLC boosted its stake in Xeris Biopharma by 31.4% in the fourth quarter. Janney Montgomery Scott LLC now owns 23,000 shares of the company’s stock valued at $78,000 after acquiring an additional 5,500 shares in the last quarter. Finally, Prudential Financial Inc. boosted its stake in Xeris Biopharma by 23.4% in the fourth quarter. Prudential Financial Inc. now owns 36,945 shares of the company’s stock valued at $125,000 after acquiring an additional 7,000 shares in the last quarter. 42.75% of the stock is currently owned by institutional investors.

About Xeris Biopharma

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.